Replies to post #54291 on Biotech Values

[DewDiligence]

Re: GS9190 non-nuke for HCV

GILD’s CSO, Norbert Bischofberger, said on today’s CC that the QT-prolongation issue with GS9190 is “clinically manageable.” Nonetheless, more dosing studies will be conducted before proceeding to larger efficacy trials.